Wall Street analysts expect Orgenesis Inc. (NYSE:ORGS) to report sales of $6.86 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Orgenesis’ earnings, with the lowest sales estimate coming in at $4.22 million and the highest estimate coming in at $9.50 million. Orgenesis reported sales of $2.64 million during the same quarter last year, which indicates a positive year-over-year growth rate of 159.8%. The business is expected to report its next quarterly earnings report on Monday, May 20th.
On average, analysts expect that Orgenesis will report full year sales of $39.08 million for the current fiscal year, with estimates ranging from $32.66 million to $45.50 million. For the next fiscal year, analysts forecast that the business will report sales of $58.17 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Orgenesis.
Orgenesis (NYSE:ORGS) last issued its quarterly earnings results on Wednesday, February 13th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.18). The firm had revenue of $5.80 million for the quarter, compared to analyst estimates of $7.78 million.
Orgenesis Company Profile
Orgenesis Inc, a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. It operates through two segments, Contract Development and Manufacturing Organizations (CDMO) and Cellular Therapy (CT) Business.
See Also: Why do companies pay special dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.